Notícias Madrigal Pharmaceuticals Inc - MDGL | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Madrigal Pharmaceuticals Inc (MDGL)
Madrigal Pharmaceuticals Inc (MDGL) Notícias

Madrigal Pharmaceuticals Inc (MDGL)

329,24

12,15

(3,83%)

Fechado 22 Novembro 6:00PM

Atrasado por 15 minutos

329,24

-0,13

(-0,04%)

Após o horário de negociação: 8:41PM

Atrasado por 15 minutos

Seu centro para cotações em tempo real, discussões ao vivo e novas ideias.

Form 144 - Report of proposed sale of securities

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Madrigal Pharmaceuticals, Inc. Announces Participation at Three Upcoming Investor Conferences

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates

Madrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting®

Madrigal Pharmaceuticals Completes Enrollment of Clinical Outcomes Study of Resmetirom in Patients with Compensated NASH/MASH Cirrhosis

Madrigal Pharmaceuticals to Release Third-Quarter 2024 Financial Results and Host Webcast on October 31, 2024

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Madrigal Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições